<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Argen-x — News on 6ix</title>
    <link>https://6ix.com/company/argen-x</link>
    <description>Latest news and press releases for Argen-x on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Sat, 18 Apr 2026 05:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/argen-x" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836199478dffbe2df13e6c6.webp</url>
      <title>Argen-x</title>
      <link>https://6ix.com/company/argen-x</link>
    </image>
    <item>
      <title>argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP</title>
      <link>https://6ix.com/company/argen-x/news/argenx-brings-neuromuscular-leadership-to-aan-2026-with-new-data-supporting-broader-vyvgart-use-across-mg-and-cidp</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-brings-neuromuscular-leadership-to-aan-2026-with-new-data-supporting-broader-vyvgart-use-across-mg-and-cidp</guid>
      <pubDate>Sat, 18 Apr 2026 05:00:00 GMT</pubDate>
      <description>ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient populationADAPT SERON, OCULUS, and Jr study results build on VYVGART&apos;s approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis supports earlier use of VYVGART in treatment-naïve CIDP patients, with 87.5% achieving early benefit April 18, 202</description>
    </item>
    <item>
      <title>argenx announces Annual General Meeting of Shareholders on May 6, 2026</title>
      <link>https://6ix.com/company/argen-x/news/argenx-announces-annual-general-meeting-of-shareholders-on-may-6-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-announces-annual-general-meeting-of-shareholders-on-may-6-2026</guid>
      <pubDate>Fri, 20 Mar 2026 04:00:00 GMT</pubDate>
      <description>March 20, 2026 Amsterdam, the Netherlands – argenx SE (Euronext &amp; Nasdaq: ARGX), a global immunology company committed to improving the lives of people</description>
    </item>
    <item>
      <title>argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline</title>
      <link>https://6ix.com/company/argen-x/news/argenx-to-present-new-data-at-2026-aan-annual-meeting-that-continue-to-transform-patient-outcomes-in-mg-and-cidp-and-build-upon-strength-of-pipeline-9</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-to-present-new-data-at-2026-aan-annual-meeting-that-continue-to-transform-patient-outcomes-in-mg-and-cidp-and-build-upon-strength-of-pipeline-9</guid>
      <pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
      <description>Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data</description>
    </item>
    <item>
      <title>argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis</title>
      <link>https://6ix.com/company/argen-x/news/argenx-announces-positive-topline-results-from-phase-3-adapt-oculus-trial-of-vyvgart-in-ocular-myasthenia-gravis</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-announces-positive-topline-results-from-phase-3-adapt-oculus-trial-of-vyvgart-in-ocular-myasthenia-gravis</guid>
      <pubDate>Thu, 26 Feb 2026 05:30:00 GMT</pubDate>
      <description>Study met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMG Regulated Information – Inside Information February 26, 2026, 6:30 AM CET Amsterdam, the Netherlands – argenx SE (Euronext &amp; Nasdaq: ARGX), a global immunology company committed to improving the</description>
    </item>
    <item>
      <title>argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update</title>
      <link>https://6ix.com/company/argen-x/news/argenx-reports-full-year-2025-financial-results-and-provides-fourth-quarter-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-reports-full-year-2025-financial-results-and-provides-fourth-quarter-business-update</guid>
      <pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
      <description>$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in</description>
    </item>
    <item>
      <title>argenx to Present at TD Cowen 46th Annual Healthcare Conference</title>
      <link>https://6ix.com/company/argen-x/news/argenx-to-present-at-td-cowen-46th-annual-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-to-present-at-td-cowen-46th-annual-healthcare-conference</guid>
      <pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
      <description>February 23, 2026Amsterdam, the Netherlands – argenx (Euronext &amp; Nasdaq: ARGX), a global immunology company committed to improving the lives of people</description>
    </item>
    <item>
      <title>argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026</title>
      <link>https://6ix.com/company/argen-x/news/argenx-to-report-full-year-2025-financial-results-and-fourth-quarter-business-update-on-february-26-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-to-report-full-year-2025-financial-results-and-fourth-quarter-business-update-on-february-26-2026</guid>
      <pubDate>Thu, 19 Feb 2026 06:00:00 GMT</pubDate>
      <description>February 19, 2026Amsterdam, the Netherlands – argenx (Euronext &amp; Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 26, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2025 financial results and provide a fourth quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx w</description>
    </item>
    <item>
      <title>argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG</title>
      <link>https://6ix.com/company/argen-x/news/argenx-announces-fda-acceptance-supplemental-biologics-license-application-priority</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-announces-fda-acceptance-supplemental-biologics-license-application-priority</guid>
      <pubDate>Tue, 13 Jan 2026 05:00:00 GMT</pubDate>
      <description>January 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext &amp; Nasdaq: ARGX), a global immunology company committed to improving the lives</description>
    </item>
    <item>
      <title>argenx Highlights 2026 Strategic Priorities</title>
      <link>https://6ix.com/company/argen-x/news/argenx-highlights-2026-strategic-priorities-2026-01-12</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-highlights-2026-strategic-priorities-2026-01-12</guid>
      <pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
      <description>Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales</description>
    </item>
    <item>
      <title>argenx to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/argen-x/news/argenx-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</guid>
      <pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
      <description>January 6, 2026Amsterdam, the Netherlands – argenx (Euronext &amp; Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering</description>
    </item>
    <item>
      <title>argenx Announces Leadership Transition Marking Next Evolution of Growth</title>
      <link>https://6ix.com/company/argen-x/news/argenx-announces-leadership-transition-marking-next-evolution-growth-2026-01-05</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-announces-leadership-transition-marking-next-evolution-growth-2026-01-05</guid>
      <pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
      <description>Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and</description>
    </item>
    <item>
      <title>argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease</title>
      <link>https://6ix.com/company/argen-x/news/argenx-provides-update-uplighted-studies-efgartigimod-sc-thyroid-eye-disease-2025-12</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-provides-update-uplighted-studies-efgartigimod-sc-thyroid-eye-disease-2025-12</guid>
      <pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
      <description>15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext &amp; Nasdaq: ARGX), a global immunology company committed to improving the lives</description>
    </item>
    <item>
      <title>argenx Announces Results of Extraordinary General Meeting of Shareholders</title>
      <link>https://6ix.com/company/argen-x/news/argenx-announces-results-extraordinary-general-meeting-shareholders-2025-11-18</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-announces-results-extraordinary-general-meeting-shareholders-2025-11-18</guid>
      <pubDate>Tue, 18 Nov 2025 05:00:00 GMT</pubDate>
      <description>November 18, 2025 – 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext &amp; Nasdaq: ARGX), a global immunology company committed to improving the</description>
    </item>
    <item>
      <title>/C O R R E C T I O N from source -- argenx Canada Inc./</title>
      <link>https://6ix.com/company/argen-x/news/argenx-announces-vyvgart-sc-prefilled-145100607</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-announces-vyvgart-sc-prefilled-145100607</guid>
      <pubDate>Wed, 05 Nov 2025 20:30:00 GMT</pubDate>
      <description>argenx SE (EURONEXT: ARGX) (Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Health Canada has issued a Notice of Compliance authorizing VYVGART SC (efgartigimod alfa injection) as a monotherapy for the treatment of adult patients with active chronic inflammatory demyelinating polyneuropathy (CIDP).</description>
    </item>
    <item>
      <title>argenx Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/argen-x/news/argenx-reports-third-quarter-2025-financial-results-and-provides-business-update-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-reports-third-quarter-2025-financial-results-and-provides-business-update-2025</guid>
      <pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
      <description>$1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 –</description>
    </item>
    <item>
      <title>argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients</title>
      <link>https://6ix.com/company/argen-x/news/argenx-presents-new-data-aanem-and-mgfa-highlighting-strength-and-broad-benefit</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-presents-new-data-aanem-and-mgfa-highlighting-strength-and-broad-benefit</guid>
      <pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
      <description>VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in</description>
    </item>
    <item>
      <title>argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025</title>
      <link>https://6ix.com/company/argen-x/news/argenx-report-third-quarter-2025-financial-results-and-business-update-october-30</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-report-third-quarter-2025-financial-results-and-business-update-october-30</guid>
      <pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
      <description>October 23, 2025Amsterdam, the Netherlands – argenx (Euronext &amp; Nasdaq: ARGX), a global immunology company committed to improving the lives of people</description>
    </item>
    <item>
      <title>argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session</title>
      <link>https://6ix.com/company/argen-x/news/argenx-highlight-key-data-and-breadth-immunology-innovation-2025-aanem-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-highlight-key-data-and-breadth-immunology-innovation-2025-aanem-annual-meeting</guid>
      <pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
      <description>Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world evidence and</description>
    </item>
    <item>
      <title>argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025</title>
      <link>https://6ix.com/company/argen-x/news/argenx-announces-extraordinary-general-meeting-shareholders-november-18-2025-2025-10</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/argenx-announces-extraordinary-general-meeting-shareholders-november-18-2025-2025-10</guid>
      <pubDate>Fri, 03 Oct 2025 04:00:00 GMT</pubDate>
      <description>October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext &amp; Nasdaq: ARGX), a global immunology company committed to improving the lives of people</description>
    </item>
    <item>
      <title>FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations</title>
      <link>https://6ix.com/company/argen-x/news/fujifilm-biotechnologies-expands-strategic-partnership-with-argenx-to-include-us-manufacturing-operations</link>
      <guid isPermaLink="true">https://6ix.com/company/argen-x/news/fujifilm-biotechnologies-expands-strategic-partnership-with-argenx-to-include-us-manufacturing-operations</guid>
      <pubDate>Thu, 18 Sep 2025 13:00:00 GMT</pubDate>
      <description>HOLLY SPRINGS, N.C., September 18, 2025--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced a significant expansion of its global partnership with argenx SE, a global immunology company. As part of the expanded agreement, FUJIFILM Biotechnologies will initiate manufacturing of argenx’ drug substance for efgartigimod at the Holly Springs, North Carolina, site in 2028.</description>
    </item>
  </channel>
</rss>